Navigation Links
Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
Date:7/31/2013

BOSTON, July 31, 2013 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery and development biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a Phase I Small Business Technology Transfer  (STTR) award from the National Cancer Institute of the National Institutes of Health. The Phase 1 award supports the research and development of Arisaph's small molecule immune modulators to stimulate tumor immunity following treatment with BRAF inhibitors in cancer. Following the successful completion of the research, the Company may be eligible for up to $2 million of additional Phase 2 funding to further the development of its immune modulator program for the treatment of melanoma. To date, Arisaph has received in excess of $55 million of non-dilutive capital, including $2.8 million awarded under the U.S. government's Therapeutics Discovery Project Program (TDPP) and $37 million from royalty monetizations leveraging the Company's DPP 4 inhibitor patent estate.

(Logo: http://photos.prnewswire.com/prnh/20110321/NE69091LOGO )

"We are delighted to receive our third small business grant from the NIH in support of our promising oncology programs, which could enhance the efficacy of existing therapies, such as BRAF inhibitors, for the treatment of melanoma," said Christopher P. Kiritsy, President and Chief Executive Officer. "This award continues the string of government grants and other non-dilutive support, enabling the Company to advance its pipeline in an investor friendly manner."

Arisaph has leveraged its medicinal chemistry expertise to develop a class of small molecule immune modulators to boost the immune system to fight various cancers. Such immune modulators are expected to enhance the efficacy of various therapeutic antibodies (e.g., mAbs for tumor killing or for immunomodulation) and small molecule anti-cancer agents, such as BRAF inhibitors to treat colon cancer, melanoma and possibly other solid tumors. The Company also is developing tumor activated prodrugs, which are largely inactive in general circulation, but selectively activated by a specific enzyme that is up-regulated in tumor tissue to release anti-cancer warheads. This platform technology has led to the discovery of a lead tumor activated proteosome inhibitor and a lead tumor activated doxorubicin for treatment of a range of cancers.About ArisaphArisaph Pharmaceuticals Inc, an emerging biopharmaceutical company located in Boston, Massachusetts, was founded by Dr. William Bachovchin (Professor of Biochemistry, Tufts University School of Medicine), Christopher Kiritsy (Former EVP Corporate Development and CFO Kos Pharmaceuticals, Inc.) and Michael Jaharis (Founder, Chairman Emeritus, Kos Pharmaceuticals, Inc.) to develop differentiated therapies for cardiometabolic diseases and cancer.  Arisaph employs rational drug design approaches to develop differentiated new chemical entities (NCEs) that are highly potent and act on select, validated targets. By focusing its drug development activities on validated targets, the Company believes that the risks associated with new chemical entity development can be mitigated compared with developing first-in-class compounds for nonvalidated targets. Arisaph has developed a rich pipeline of products at various stages of preclinical and clinical development, including a differentiated niacin analog being developed for the treatment of dyslipidemia.  The Company's vision is to create a fully integrated pharmaceutical company leveraging its drug discovery expertise to develop transformational, patent protected, medicines that offer distinct safety, efficacy and/or tolerability benefits compared with existing therapies for large markets, whose needs are not being fully met by current therapeutics.Certain statements in this press release, including statements regarding the Company's research and development effort, the Company's ability to finance its development programs into initial human clinical testing, and the Company's ability to successfully capitalize on the early stage research are subject to risks and uncertainties. These risks and uncertainties include risks and uncertainties related to:  our ability to discover and develop new compounds and products using a novel approach to drug discovery; the early stage of all of our discovery and development efforts; our ability successfully to complete preclinical and clinical development of our products; our ability to obtain and maintain regulatory approvals for our products; competition from other technologies and technologies similar to ours; obtaining, maintaining and protecting intellectual property utilized by our products; changes in legislation and regulations affecting our products and potential product candidates; our need to obtain additional funding to support our business activities; our dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the ability of our licensees to achieve developmental, regulatory and other milestones and to commercialize their products; the effect of conditions in the pharmaceutical industry and the economy in general, as well as certain other risks and uncertainties.  Grants reported in this press release was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R41CA174008, 1R41CA174031-01, and 1R41CA156930-01A1.Contact

Arisaph Pharmaceuticals, Inc.Christopher KiritsyPresident and CEO(617) 986-4500


'/>"/>
SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A new ... thermoplastics and other highly-engineered materials, is being launched ... tubing has been developed in recent years to ... therapies and surgical applications. More expensive materials such ... produce microextrusion tubing due to their ability to ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
(Date:5/2/2017)... May 2, 2017  CIVCO Radiotherapy, the leading ... announced today that Nat Geissel has ... since 2012 and has served as vice president ... president and general manager, and most recently, executive ... am extremely proud of what CIVCO Radiotherapy and ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a ... survey in an infographic on the current state of anxiety in support of National ... anxiety, was conducted in April 2017 and benchmarked general anxiety levels as well as ...
(Date:5/22/2017)... ... 2017 , ... The American Academy of Thermology ... and clinical application of medical infrared imaging, has announced two new educational offerings ... services. , The first new educational offering is an online self-directed Physician Member ...
(Date:5/22/2017)... ... May 22, 2017 , ... Dr. Kiya Green, a ... periodontal plastic surgery treatments, including crown lengthening and gum reduction surgery, ... esthetic and functional procedures to help patients improve their oral health, reduce gummy ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... An inventor ... write with a pen. "My wife’s hand was damaged in a firework accident, so ... that helps people with manual problems." , He then designed and created a prototype ...
(Date:5/22/2017)... ... , ... Galena, Alaska, has a population of less than 500 people. But, ... targeted to build a nuclear plant by the TOSHIBA Corporation. , In “The Galena ... describes the journey to get power to his small town, off the electrical grid. ...
Breaking Medicine News(10 mins):